Results 261 to 270 of about 215,808 (286)

Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations

Clinical Pharmacology in Drug Development, 2017
AbstractDesvenlafaxine exposure in Korean and US populations was compared using population pharmacokinetic (PK) analysis. Data from a single‐ and multiple‐dose study of desvenlafaxine (50, 100, and 200 mg) in 30 healthy Korean subjects were added to a population PK model previously developed using sparse PK samples from patients with major depressive ...
Alice I, Nichols, Sam, Liao, Richat, Abbas   +2 more
openaire   +2 more sources

Parametric Approaches in Population Pharmacokinetics

The Journal of Clinical Pharmacology, 2020
AbstractPopulation pharmacokinetic (popPK) approaches have spread widely throughout clinical pharmacology research, and every clinician should have some understanding of them. After a general introduction on the fundamentals and fields of application of these approaches, this review focuses on parametric popPK methods to provide the clinicians with the
Monia Guidi, Chantal Csajka, Thierry Buclin   +2 more
openaire   +2 more sources

Population Pharmacokinetics III: Design, Analysis, and Application of Population Pharmacokinetic Studies

Annals of Pharmacotherapy, 2004
OBJECTIVE To present a framework within which population pharmacokinetic (PPK) studies should be designed and analyzed and discuss the application of developed PPK models. METHODS Information on PPK was retrieved from a MEDLINE search (1979–December 2003) of the literature and a bibliographic evaluation of review articles and books. This information is
Ene I, Ette, Paul J, Williams, James R, Lane   +2 more
openaire   +2 more sources

Population pharmacokinetics

Abstract The role of population pharmacokinetics in drug development is introduced.
Phil Ambery, Adrian Kilcoyne, Daniel O’Connor   +2 more
openaire   +1 more source

Population Pharmacokinetic Models

Drug Investigation, 1993
The availability of personal computer programs for individualising drug dosage regimens has stimulated interest in modelling population pharmacokinetics. Appropriate use of population models requires knowledge of the distribution of their pharmacokinetic parameter values.
Warren F. Dodge, Roger W. Jelliffe, C. Joan Richardson, Renee A. Bellanger, James A. Hokanson, Wayne R. Snodgrass   +5 more
openaire   +1 more source

Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel

Investigational New Drugs, 2001
The population approach has been implemented prospectively in the clinical development of docetaxel (Taxotere). Overall 640 patients were evaluable for the population PK/PD analysis. The PK analysis evidenced significant covariates explaining the inter-patient variability of docetaxel clearance and the PK/PD analysis demonstrated that the variability ...
R, Bruno, N, Vivier, C, Veyrat-Follet, G, Montay, G R, Rhodes   +4 more
openaire   +2 more sources

Population Pharmacokinetic Analysis of Bisoprolol

Clinical Pharmacokinetics, 1989
The technique of population pharmacokinetic analysis was employed to study the variability in the dose concentration relationship of bisoprolol during its clinical development. The influence of demographic factors on the variability of clearance was investigated in 3 different populations: group I, patients (including an elderly group) with essential ...
J, Grevel, P, Thomas, B, Whiting
openaire   +2 more sources

Population Pharmacokinetics of Polymyxin B

Clinical Pharmacology & Therapeutics, 2018
Polymyxin B is used as a last treatment resort for multidrug‐resistant Gram‐negative bacterial infections. The objectives of this study were to examine the population pharmacokinetics of polymyxin B and investigate factor(s) influencing pharmacokinetic variability.
Pooja, Manchandani, Visanu, Thamlikitkul, Yanina, Dubrovskaya, Jessica T, Babic, David C, Lye, Lawrence S, Lee, Vincent H, Tam   +6 more
openaire   +2 more sources

Population Pharmacokinetics in Geriatric Psychiatry

The American Journal of Geriatric Psychiatry, 2006
Although geriatric patients are the major recipients of drugs, most research during drug development is conducted in healthy younger adults. Safe and effective drug therapy in the elderly requires an understanding of both drug disposition and response in older individuals.
Kristin L, Bigos, Robert R, Bies, Bruce G, Pollock   +2 more
openaire   +2 more sources

Population Pharmacokinetics/Dynamics*

Annual Review of Pharmacology and Toxicology, 1992
L B, Sheiner, T M, Ludden
openaire   +3 more sources